• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Israel News

#Israel: Israel in social media

  • About
  • Sponsored Post
  • Contact

Teva to Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets to Hospitals Nationwide

March 19, 2020 By admin

Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month

TEL AVIV, Israel & PARSIPPANY, N.J. – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.

“We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost,” said Brendan O’Grady, Teva Executive Vice President, North America Commercial. “Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately.”

Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month.

Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients.

Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.

Source: Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
www.tevapharm.com

Filed Under: Featured Posts Tagged With: Covid-19

Footer

Recent Posts

  • Behind the Beautiful Facade of Jaffa, a Troubling Series of Violent Crimes
  • Vine Ventures Closes $236 Million Fund III to Back US-Israel Tech, Its Largest Fund Yet
  • Tel Aviv Stock Exchange (TASE) Q3 2026 Profit Jumps 37 Percent as Market Cap Hits NIS 3.1 Trillion
  • Thailand Is Becoming Increasingly Anti-Israel
  • Likud Flips Qatargate on the Arab Parties One Day After the Vote
  • TASE Votes Against Netanyahu
  • The Shekel Votes Against Netanyahu
  • Israel Election 2026 Partial Count Puts Netanyahu Bloc Short of a Majority, Projection 53 to 55 Seats
  • Why I Voted for Naftali Bennett Today
  • Netanyahu Reeks of Desperation

Media Partners

  • Cybersecurity Market
  • Technology Conferences
Azul Ships Java4Shell Fixes as AI Vulnerability Discovery Outpaces Enterprise Patching
SBC Medical Group Reports Cyberattack Affecting 1.6 Million Customer Records in Japan
AI Platform Xint Finds Five Nginx RCE Flaws as Wiz Reports the Same Bugs Independently
Billington Critical Infrastructure CyberSecurity Summit 2026, November 17-18, Henry B. Gonzalez Convention Center, San Antonio
Corma Raises $125M Series A at a $1B Valuation Three Months After Its Sequoia Seed
Tanium Converge 2026, November 16-19, ARIA Resort and Casino, Las Vegas
IBM and CrowdStrike Move to Control Enterprise AI Agents
Anyday Security Launches ExploitTotal.ai With 200 AI-Built Exploits, 72% for Bugs That Had No Public Exploit
Redspin Earns ISO 17020 Accreditation as One of the First CMMC Assessors as DQS Certifies Samsung Display Automotive Cybersecurity
Vanta Launches the Vanta Trusted Network to Turn Compliance Partners Into Recurring GRC Practices
December 1, 2026 Investor Conferences, UBS Industrials, Evercore Healthcare and Morgan Stanley Consumer and Retail
Morgan Stanley European TMT Conference 2026, November 18-19, Barcelona
Roth Technology Conference 2026, November 17-18, Hard Rock Hotel, New York
Barclays Global Technology Conference 2026, December 9-10, San Francisco
Wells Fargo TMT Summit 2026, December 8, Rancho Palos Verdes
UBS Global Technology and AI Conference 2026, November 30–December 2, Scottsdale
Tanium Converge 2026, November 16-19, ARIA Resort and Casino, Las Vegas
Kinaxis Kinexions India 2026, November 17-18, Mumbai
Aspen Cyber Summit 2026, November 18, Washington DC
Solana Breakpoint 2026, November 15-17, Olympia London, London

Media Partners

  • Defense Market
  • Technologies.org
UFORCE Raises 700 Million Dollars at a 6 Billion Dollar Valuation as Raytheon Adds Ursa Major and Avio USA as Second Tomahawk Booster Suppliers
Materialise Calls for a Coordinated European Defense Manufacturing Network
Starfighters Space Joins the Exos Aerospace Team Bidding for Air Force AEDC Test Infrastructure Work With Mach 2 F-104 Jets
BigBear.ai (BBAI) Wins Europe-Wide ECAC Certification for Pangiam AI Baggage Screening
Astronics (ATRO) Posts Record Operating Income on 28 Percent Sales Growth as Aerospace Margins Reach 23 Percent
Palladyne AI Grows Revenue 895 Percent While Swarmer Books 26 Thousand Dollars and Bets on a Ukrainian Ground Robot Maker
AEVEX (AVEX) Wins an IDIQ With a Ceiling of Nearly 400 Million Dollars for Unmanned Aircraft Systems
Rheinmetall ICEYE Picks Manufacturo to Run Its SAR Satellite Line as Electra Wins a 4.7 Million Dollar Air Force Contract and First Graphene Gets a Bigger US Defence Order
Japan Picks Rakuten and AST SpaceMobile for J-LEO, a Sovereign Satellite-to-Phone Network Worth About 1 Billion Dollars Over Three Years
NASA Picks Astranis for a 264 Million Dollar TDRS Relay Replacement as Stoke Space Gets Room for a Second Cape Pad
Palo Alto Networks to Buy Applied Compute for $4.5 Billion in Stock as It Moves Into Custom Open-Weight AI Models
Saltgrain and NTT Research Show Post-Quantum Attribute-Based Encryption Fast Enough for a Laptop
Quantum Moves Into the Supercomputer Queue as IQM, Altera and Infleqtion Report Progress
Penguin Solutions and Marvell Bet on Photonics to Break the GPU Memory Wall
TensorWave Signs Six-Year Deal to Supply OpenAI With 457MW of AMD Helios Capacity
LangChain Raises $300 Million at a $3 Billion Valuation to Build Out LangSmith Agent Platform
OQFT Shows Where the Quantum Fourier Transform Can Get Shallower
MemryX MX3+ Targets 1 POPS for Edge AI as Tianji Shows a 21-Joint Robot Hand at CoRL and Appear Starts Solid-State Battery Pre-Production
Adobe MAX 2026 Opens Photoshop and Premiere to Outside AI Agents and Deepens Its Google Partnership
Zendesk Launches Outcome AI Platform and Drops Seat Limits From New Plans

Copyright © 2015 IsraelNews.org

Technologies, Market Analysis & Market Research Reports, Photography

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT